4.8 Article

Branched Antisense and siRNA Co-Assembled Nanoplatform for Combined Gene Silencing and Tumor Therapy

Journal

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
Volume 60, Issue 4, Pages 1853-1860

Publisher

WILEY-V C H VERLAG GMBH
DOI: 10.1002/anie.202011174

Keywords

cancer therapy; drug delivery; gene therapy; nucleic acid nanostructure; self-assembly

Funding

  1. National Natural Science Foundation of China [21708004, 21721002]
  2. National Basic Research Program of China [2016YFA0201601, 2018YFA0208900]
  3. Beijing Municipal Science & Technology Commission [Z191100004819008]
  4. Strategic Priority Research Program of Chinese Academy of Sciences [XDB36000000]
  5. Key Research Program of Frontier Sciences, CAS [QYZDB-SSW-SLH029]
  6. CAS Interdisciplinary Innovation Team
  7. K. C. Wong Education Foundation [GJTD-2018-03]

Ask authors/readers for more resources

This study presents a novel strategy for constructing a nanoplatform that combines branched antisense DNA and siRNA for gene silencing. The multifunctional nucleic acid nanosystem efficiently inhibits tumor growth by targeting the tumor-associated gene PLK1 through combined gene silencing.
Chemically modified DNA has been widely developed to fabricate various nucleic acid nanostructures for biomedical applications. Herein, we report a facile strategy for construction of branched antisense DNA and small interfering RNA (siRNA) co-assembled nanoplatform for combined gene silencing in vitro and in vivo. In our design, the branched antisense can efficiently capture siRNA with 3 ' overhangs through DNA-RNA hybridization. After being equipped with an active targeting group and an endosomal escape peptide by host-guest interaction, the tailored nucleic acid nanostructure functions efficiently as both delivery carrier and therapeutic cargo, which is released by endogenous RNase H digestion. The multifunctional nucleic acid nanosystem elicits an efficient inhibition of tumor growth based on the combined gene silencing of the tumor-associated gene polo-like kinase 1 (PLK1). This biocompatible nucleic acid nanoplatform presents a new strategy for the development of gene therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available